Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Albert David's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -67.07%.
The historical rank and industry rank for Albert David's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:ALBERTDAVD'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.37 Med: 31.4 Max: 113.49
Current: 2.49
During the past 13 years, Albert David's highest ROC (Joel Greenblatt) % was 113.49%. The lowest was 2.37%. And the median was 31.40%.
NSE:ALBERTDAVD's ROC (Joel Greenblatt) % is ranked worse than 64.49% of 980
companies
in the Drug Manufacturers industry
Industry Median: 10.745
vs NSE:ALBERTDAVD: 2.49
Albert David's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -34.40% per year.
Albert David (NSE:ALBERTDAVD) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Albert David ROC (Joel Greenblatt) % Related Terms
Albert David ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Albert David's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ALBERTDAVD vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Albert David's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Albert David ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Albert David's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Albert David's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -67.07% mean?
Albert David (NSE:ALBERTDAVD) has a ROC (Joel Greenblatt) % of -67.07% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Albert David and its competitors. Over the past decade, Albert David's ROC (Joel Greenblatt) % has ranged from 2.37 to 113.49. According to the industry distribution chart, Albert David ranks #632 out of 980 companies in the Drug Manufacturers industry, placing it in the top 64.5%.
Is Albert David's ROC (Joel Greenblatt) % too high?
Albert David's current ROC (Joel Greenblatt) % is -67.07%. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 113.49. Based on the distribution chart, Albert David ranks #632 out of 980 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Albert David has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Albert David's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Albert David ranks #632 out of 980 companies for ROC (Joel Greenblatt) %. This places Albert David in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 10.75. Historically, Albert David's own ROC (Joel Greenblatt) % has ranged from 2.37 to 113.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.75, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Albert David and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Albert David's current ROC (Joel Greenblatt) % is -67.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert David stock overvalued right now?
Based on GuruFocus' analysis, Albert David (NSE:ALBERTDAVD) is currently considered Fairly Valued. The stock's GF Value™ is ₹818.05, compared to a current price of ₹812.50 — trading 0.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is -67.07%. Albert David's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Albert David (NSE:ALBERTDAVD), the current ROC (Joel Greenblatt) % is -67.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Albert David (NSE:ALBERTDAVD) Overvalued in 2026?
Based on GuruFocus' analysis, Albert David stock appears to be undervalued.
The current stock price of ₹812.50 is trading 0.7% below its estimated GF Value™ of ₹818.05.
GuruFocus considers Albert David to be Fairly Valued.
Key valuation signals for NSE:ALBERTDAVD:
ROC (Joel Greenblatt) %: -67.07%
GF Value™: ₹818.05 vs. price of ₹812.50 (0.7% below fair value)
No single metric tells the full story. See the NSE:ALBERTDAVD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Albert David Ltd is engaged in the manufacturing and trading of pharmaceutical products. The company offers products such as pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs. Its formulation product covers parenteral, oral, enteral, topical agents, and vision care solutions. The company exports its product to regions like Latin America, Southeast Asia, and a few African countries. The Company is only engaged in the manufacturing of pharmaceutical products, ipso facto, one reportable segment.
72GF Score
Get the complete analysis for NSE:ALBERTDAVD
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALBERTDAVD has been successfully added to your 
